BRIEF—Insulin market set to grow at 10% annually, analyst says

A report into the global human insulin market projects that revenues from therapies in this area will grow by over 10% per year, over the next five years.

The authors attribute the growth in the market, which is currently dominated by Novo Nordisk, Sanofi, and Eli Lilly, to the increasing prevalence of diabetes and obesity, as well as ageing populations.

The report warns, however, that the market is held back by “the high cost for the development and production of insulin, manufacturing complexities, and a stringent regulatory setting for the approval of derived products.”

Other major players in this area include Wockhardt, Biocon, Julphar, Oramed, GlaxoSmithKline, and SemBioSys Genetics.